Skip to main content
S&P 5007,656.98+0.86%DOW52,573.29+0.98%NASDAQ26,333.03+0.96%BTC$77,379.00+0.25%ETH$2,539.05+3.24%GOLD$4,390.00-0.39%OIL$99.99-2.43%
Smart Investors Daily
Codexis, Inc. logo

NASDAQ · CDXS

Codexis, Inc.

Healthcare · Biotechnology

$1.44

Up+$0.03 (+1.74%)

Updated Sep 11, 2026, 9:17 PM

SID Score

3.9/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
144.21M
P/E ratio
-2.4
Dividend yield
0.00%
52-week range
$0.96 – $2.98
Volume
467.31K
Avg. volume
910.65K

Price performance

CDXS price history

1M range · 0 trading sessions · Daily adjusted prices

CDXS does not have enough price history for the selected period.

Data unavailable

Market data is busy. Please try again shortly.

Latest CDXS news

The latest Smart Investors Daily articles mentioning CDXS.

Stock researchCompany · Overview

CDXS research

Overview

Company profile and research snapshot.

Company profile

Codexis Inc is a provider of enzymatic solutions for efficient and scalable therapeutics manufacturing that leverages its proprietary CodeEvolver technology platform to discover, develop, and enhance novel, high-performance enzymes. Codexis enzymes solve challenges associated with small molecule pharmaceuticals manufacturing and nucleic acid synthesis. The Company is currently developing its proprietary ECO Synthesis manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. Codexis' enzymes can drive improvements such as higher yields, reduced energy usage and waste generation, improved efficiency in manufacturing and greater sensitivity in genomic and diagnostic applications. Geographically, it derives maximum revenue from the Americas.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Buy
Average target
$11.00
Implied upside
—
Analysts
13
CDXS recent ratings
DateFirmRatingTarget
Aug 17, 2026Piper SandlerOverweight—
Nov 22, 2024Cantor FitzgeraldOverweight—
Nov 15, 2024Cantor FitzgeraldOverweight—
Nov 4, 2024BenchmarkHold—
Sep 20, 2024Cantor FitzgeraldOverweight—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Aug 27, 2026

Codexis to Participate in Cantor Global Healthcare Conference 2026

REDWOOD CITY, Calif., Aug. 27, 2026 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable manufacturing of complex therapeutics, today announced the Company will attend the Cantor Global Healthcare Conference 2026, being held September 9-11, 2026, in New York, New York. Management will participate in a fireside chat on Thursday, September 10, 2026, at 9:45 am ET. A live webcast of the event will be available in the Investor Relatio

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By